Media
Press Releases
February 17, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Business Wire
January 31, 2021
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
globenewswire.com
In The News
Beigene strikes its second overseas deal this year with BITT for TNFR2 antibodies
BioWorld | 2021-02-23
A month after multi-billion dollar Novartis deal, BeiGene follows up with ‘reverse’ deal
Endpoints News
BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement
Chinabiotoday.com
BioCentury Emerging Company Profile (PDF)
BioCentury | March 2018
Publications on TNF Superfamily Antagonism
Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions | Nature Communications
March 24, 2020
Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL – PubMed (nih.gov)
August 5, 2019
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches – PubMed (nih.gov)
May 28, 2018
Frontiers | TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors | Immunology (frontiersin.org)
January 2, 2018
Structural principles of tumor necrosis factor superfamily signaling | Science Signaling (sciencemag.org)